Portfolio company
Crystalys Therapeutics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
12 investors
Sectors
About
Crystalys Therapeutics develops a daily oral treatment for patients with gout to manage uric acid levels and prevent inflammatory flares.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
BEO Therapeutics
This company develops oral microbiome therapies to treat patients with gouty arthritis and chronic kidney disease by reducing metabolic waste products.
Areteia Therapeutics
The company develops an oral medication for patients with eosinophilic asthma to reduce inflammation and manage their condition.
Mineralys Therapeutics
The company develops an aldosterone synthase inhibitor medicine to treat patients with uncontrolled or treatment-resistant hypertension and chronic kidney disease.
Pathalys Pharma
This biopharmaceutical company develops treatments for secondary hyperparathyroidism in patients with end-stage kidney disease undergoing dialysis.
BioTryp
This company develops oral antibiofilm therapies to treat bacterial infections for patients, primarily focusing on individuals with urinary tract infections.
Metabolys
This biopharmaceutical company develops oral small molecules to treat metabolic diseases, specifically non-alcoholic steatohepatitis and type 2 diabetes, for the global healthcare market.
GutCRINE
This company develops microbiome-derived pharmabiotics to treat metabolic and age-related disorders including obesity and type-2 diabetes for patients with chronic diseases.
Calyx Therapeutics
This company develops oral therapies for diabetes and inflammatory diseases using natural plant extracts for pharmaceutical and biotechnology organisations.